Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

Abstract Background The role of serum fibroblast growth factor 19 (FGF19) in arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D).Methods A total of 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by the triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio were measured in those subjects. In addition, other relevant clinical data were also collected. Results Serum FGF19 levels in T2D patients were significantly lower than those in healthy controls (p < 0.05). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels (r = –0.351 and –0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV (β = –0.20, t = –2.23, p = 0.029) and AIP (β = –0.28, t = –2.66, p = 0.010).Conclusions The serum FGF19 levels were independently and inversely associated with baPWV and AIP, which indicate that serum FGF19 may have a protective role in atherosclerosis in patients with T2D.

Download Full-text

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

10.21203/rs.2.24087/v2 ◽

2020 ◽

Author(s):

Wangshu Liu ◽

Mengjie Tang ◽

Tianli Xu ◽

Jianbin Su ◽

Xue-Qin Wang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Growth Factor ◽

Arterial Stiffness ◽

Fibroblast Growth Factor ◽

Atherogenic Index ◽

Healthy Controls ◽

Fibroblast Growth ◽

Atherogenic Index Of Plasma ◽

Fibroblast Growth Factor 19

Abstract Background The role of serum fibroblast growth factor 19 (FGF19) in the arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to the arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D). Methods 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by ratio of triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) were measured in those subjects. In addition, other relevant clinical data were also collected. Results Serum FGF19 levels in T2D patients were significantly lower than that in healthy controls ( p < 0.01). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels ( r = –0.351 and –0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV ( β = –0.20, t = –2.23, p = 0.029) and AIP ( β = –0.28, t = –2.66, p = 0.010) in patients with T2D. Conclusions The serum FGF19 levels were independently and inversely associated with baPWV and AIP in patients with T2D, which indicate serum FGF19 may plays a protect role against pathogenesis of the atherosclerosis in those patients.

Download Full-text

Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

10.21203/rs.2.24087/v1 ◽

2020 ◽

Author(s):

Wangshu Liu ◽

Tianli Xu ◽

Mengjie Tang ◽

Xue-Qin Wang ◽

Jianbin Su ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Atherogenic Index ◽

Diabetic Patients ◽

Fibroblast Growth ◽

Type 2 Diabetic Patients ◽

Atherogenic Index Of Plasma ◽

Fibroblast Growth Factor 19 ◽

Type 2 Diabetic

Abstract BackgroundWe aimed to explore the relationship between serum fibroblast growth factor 19 (FGF19) and the atherogenic index of plasma (AIP) in type 2 diabetic patients.MethodsSerum FGF19 levels and lipid profiles were measured in 200 patients with type 2 diabetes (T2D). The levels of serum FGF19 were measured by ELISA. Lipid profiles were measured by enzymatic analysis. AIP and NAFLD fibrosis scores were calculated.ResultsT2D patients showed a significant decreasing trend of FGF19 concentrations depending on the tertiles of AIP (p for trend < 0.05). Simultaneously, the AIP level was closely related to the serum FGF19 level (p < 0.05). Furthermore, after adjusting for age, sex, duration, BMI, hypertension, and diabetic treatment, the correlation was still significant (p < 0.01), and it remained significant even after further adjusting for non-alcoholic fatty liver disease (NAFLD) and NAFLD fibrosis score (NFS) (p < 0.01). However, when stratified by BMI, AIP was positively correlated with FGF19 in normal-weight and overweight T2D patients but not in obese T2D subjects. After adjusting for sex, age, BMI, duration, hypertension, HbA1c, 2hPG, HOMA-IR, AIP, antidiabetic treatments, NAFLD and NFS via multiple stepwise linear regression, AIP was an independent factor affecting serum FGF19 concentrations (SE = 0.238, β = -0.290, p < 0.01).ConclusionsSerum FGF19 levels might be a good predictor for atherosclerosis and cardiovascular disease in T2D patients, especially among non-obese patients; serum FGF19 levels were significantly inversely associated with AIP.

Download Full-text